Pila Pharma has been growing earnings at an average annual rate of 12.1%, while the Pharmaceuticals industry saw earnings growing at 8.4% annually. Revenues have been growing at an average rate of 2.9% per year.
Key information
12.07%
Earnings growth rate
30.83%
EPS growth rate
Pharmaceuticals Industry Growth
7.33%
Revenue growth rate
2.85%
Return on equity
-116.10%
Net Margin
-1,509.00%
Next Earnings Update
27 Aug 2026
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Pila Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
DB:5KC Revenue, expenses and earnings (SEK Millions)
Date
Revenue
Earnings
G+A Expenses
R&D Expenses
31 Dec 25
1
-17
1
0
30 Sep 25
1
-14
1
0
30 Jun 25
1
-11
1
0
31 Mar 25
1
-11
1
0
31 Dec 24
1
-11
1
0
30 Sep 24
1
-9
1
0
30 Jun 24
1
-7
2
0
31 Mar 24
1
-8
1
0
31 Dec 23
1
-10
3
0
30 Sep 23
2
-13
9
0
30 Jun 23
2
-17
6
0
31 Mar 23
2
-20
10
0
31 Dec 22
2
-27
7
0
30 Sep 22
2
-28
9
0
30 Jun 22
2
-27
9
0
31 Mar 22
1
-25
10
0
31 Dec 21
1
-17
10
0
30 Sep 21
0
-17
8
0
31 Dec 20
0
-7
3
0
31 Dec 19
0
-9
3
0
31 Dec 18
0
-6
2
0
31 Dec 17
0
-5
3
0
31 Dec 16
0
-1
1
0
Quality Earnings: 5KC is currently unprofitable.
Growing Profit Margin: 5KC is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 5KC is unprofitable, but has reduced losses over the past 5 years at a rate of 12.1% per year.
Accelerating Growth: Unable to compare 5KC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 5KC is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (15.1%).
Return on Equity
High ROE: 5KC has a negative Return on Equity (-116.1%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
7D
1Y
7D
1Y
7D
1Y
Company Analysis and Financial Data Status
Data
Last Updated (UTC time)
Company Analysis
2026/07/03 05:35
End of Day Share Price
2026/07/03 00:00
Earnings
2025/12/31
Annual Earnings
2025/12/31
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Pila Pharma AB (publ) is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.